Traduction de «related to these five » (Néerlandais → Français) :

Novartis is unable to assess with reasonable certainty the outcome of the investigation related to these five products or the amounts, which could be material, that it might be required to pay to resolve this investigation.
Novartis est dans l’impossibilité d’évaluer, avec un degré de certitude raisonnable, l’issue probable de l’enquête concernant ces cinq produits ou les montants, susceptibles d’être importants, qu’il pourrait être amené à payer pour mettre fin à cette enquête.

Under the terms of the CIA, which has a fixed term of five years, NPC will implement additional compliance-related measures.
Selon les termes du CIA, dont la période a été fixée à cinq ans, NPC mettra en place des mesures additionnelles de mise en conformité.

NPC also resolved civil allegations under the False Claims Act relating to Trileptal and the Five Products and agreed to pay USD 237.5 million.
NPC a aussi mis un terme, dans le cadre de la «False Claims Act», aux accusations civiles liées à Trileptal et aux cinq autres produits en acceptant de payer USD 237,5 millions.

These variations will then be closed in groups with a request for clinical variation or a five-yearly renewal (RQ).
These variations will then be closed in groups with a request for clinical variation or a five-yearly renewal (RQ).

These include a historic five regulatory approvals to date in Japan for Rasilez, Tasigna, Xolair, Co-Dio and Lucentis, with regulatory decisions pending for Exforge and Galvus in the world’s second-largest pharmaceuticals market.
Celles-ci comprennent cinq autorisations de mise sur le marché au Japon, qui est le deuxième des plus importants marchés pharmaceutiques du monde, pour Rasilez, Tasigna, Xolair, Co-Dio et Lucentis, tandis que deux sont en suspens pour Exforge and Galvus.

Alcon minority shareholder litigation Beginning on January 7, 2010, shareholder class action complaints relating to the Alcon transactions announced on January 4, 2010, were filed against Novartis AG and others by minority shareholders of Alcon, Inc. These actions were filed in the SDNY, in the US Federal District Courts for the Eastern District of New York (EDNY) and the Northern District of Texas (NDTX) and in several Texas state courts.
Ces plaintes ont été déposées devant le SDNY, les tribunaux du district est de New York (EDNY), du district nord du Texas (NDTX) et devant plusieurs tribunaux de l’Etat du Texas.

Dispute with an inventor An inventor of certain patents of Novartis Vaccines & Diagnostics Inc (V&D) sued V&D in the SDNY for breach of a consulting contract and claimed he was entitled to at least a portion of settlement proceeds from arbitration proceedings relating to these patents.
Litige avec un inventeur L’inventeur de certains brevets de Novartis Vaccines & Diagnostics Inc (V&D) a poursuivi V&D devant le SDNY pour rupture d’un contrat de consultance.

These relate to: ●● Quality: GMP production, precisely known
These relate to: ●● Quality: GMP production, precisely known

Among others, these include Budget & Management Control (B&Mc), Information & Communication Technology (ICT), the Legal service, Personnel & Organisation (P&O), the Translation service, Communication & Scientific support, International Relations, PMO (the support monitoring unit), Internal Audit & Quality and the Crisis unit (non-permanent).
Among others, these include Budget & Management Control (B&Mc), Information & Communication Technology (ICT), the Legal service, Personnel & Organisation (P&O), the Translation service, Communication & Scientific support, International Relations, PMO (the support monitoring unit), Internal Audit & Quality and the Crisis unit (non-permanent).

Cash flow from financing activities included a USD 4.2 billion increase in net financial debt due to the 2010 US dollar bond issuance and USD 0.4 billion arising from treasury share transactions, principally related to sharebased compensation, but these were largely offset by the dividend payment of USD 4.5 billion .
Les flux de trésorerie des activités de financement ont inclus une augmentation d’USD 4,2 milliards de la dette financière nette due à l’émission d’un emprunt obligataire en dollars et à des transactions sur actions propres à hauteur d’USD 0,4 milliard liées à la rémunération basée sur les actions. Mais ces montants ont été largement contrebalancés par le paiement du dividende qui s’est élevé à USD 4,5 milliards.